Lanean...
Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease
First developed for clinical use in the late 1980s, the phosphodiesterase inhibitors were found to increase the levels of the ubiquitous second messenger cyclic adenosine monophosphate and could effect changes invasculartone, cardiac function, and other cellular events. After several early studies u...
Gorde:
| Argitaratua izan da: | Clin Cardiol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wiley Periodicals, Inc.
2006
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654250/ https://ncbi.nlm.nih.gov/pubmed/12058787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960250603 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|